Lv1
30 积分 2024-11-11 加入
MO07.07: First-in-Human Study of HC010, a Novel PD-1/VEGF/CTLA-4 Trispecific Antibody: Preliminary Results
22小时前
求助中
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival
1天前
已完结
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
5天前
已完结
OA14.01: Overall Survival Analysis From HARMONi-2: Ivonescimab vs Pembrolizumab as First-Line Treatment for PD-L1-Positive NSCLC
6天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
6天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
6天前
已完结
Understanding the therapeutic toolkit for inflammatory bowel disease
12天前
已完结
Beyond inflammation: the residual burden as the next target in inflammatory bowel disease
12天前
已完结
The global burden of inflammatory bowel disease: from 2025 to 2045
12天前
已完结
Artificial intelligence (AI)‐enabled RNA therapeutic design: from molecular optimization to system‐level evaluation
1个月前
已完结